



Original Article

## The Association of *cagA*, *vacA*, *babA2*, *babB* and *oipA* of *Helicobacter pylori* with Risk of Gastric Carcinoma Development

Alsaadi Zainab H<sup>1</sup>, Kadhim Hindi Nada Khazal<sup>1</sup>, Al-Marzoqi Ali H<sup>2</sup>, Memariani Mojtaba<sup>3</sup>, Kohansal Maryam<sup>4</sup>, Ghasemian Abdolmajid<sup>4\*</sup>

1. Department of Biology, College of Medicine, University of Babylon, Iraq

2. Department of Biology, College of Science for Women, University of Babylon, Iraq

3. Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

4. Noncommunicable diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran

Received: 21 Jun 2022

Accepted: 23 Oct 2022

### Abstract

**Background & Objective:** *Helicobacter pylori* (*H. pylori*), carried by more than half of the world population, is a major cause of chronic duodenal and gastric ulcers, gastritis and carcinoma. Colonization and toxin production include major virulence traits of *H. pylori*. The aim of this study was to assess the existence of *H. pylori* and virulence factors among patients with risk of gastrointestinal carcinoma (GC) in an Iraqi population.

**Materials & Methods:** During May 2016- October 2020 in Babylon, Iraq, a total of 500 biopsy samples were obtained from gastric tissue of patients with GC, gastritis, duodenitis, duodenal ulcer and gastric ulcer and cultured onto the Brucella agar. *H. pylori* isolates were identified using conventional biochemical and molecular tests. Molecular identification was conducted by amplification of *glmM* gene using the polymerase chain reaction (PCR) technique. The adhesin (*babA2*, *babB* and *oipA*) and toxin (*cagA* and *vacA*) genes were also amplified using PCR technique.

**Results:** Among 500 biopsy samples, 269 (110 from males and 159 from female patients) *H. pylori* isolates were identified. The age range of patients was 14-69 years (mean age=47.34±7.23). The *babA2* and *babB* genes were detected in 59.47% and 59.10% of isolates, respectively. Notably, *babA2* was observed in 89% of GC and 64% of DN strains being significantly more associated with GC and DN (<0.0001 and 0.028, respectively). Furthermore, *babB*-positive strains were significantly (0.042) more associated with PG. The rate of *cagA* and *vacA* was 44.60% and 48.32%, respectively. The *cagA* was detected in 64.73% of GC, and 100% of PG and DN strains with a significant association. We detected the *oipA* in 58.36% of strains which was significantly associated with GC (74%,  $P=0.0001$ ), PG (88%,  $p<0.0001$ ) and DN (84%,  $p<0.0001$ ) as compared to *oipA*-negative strains.

**Conclusion:** The existence of *H. pylori* *babA2*, *cagA* and *oipA* virulence genes was associated with GC, DN and PG. As these genes play a crucial role in the development of gastric carcinoma, accurate control measure toward hindering the colonization of pathogenic strains is essential.

**Keywords:** *Helicobacter pylori*, colonization, virulence, gastric carcinoma, duodenal cancer

### Introduction

*H. pylori* is colonized into the gastrointestinal tract of half of the world's population (1) in 10%-15% of cases development of acute gastritis, peptic ulcer diseases (PUD) and gastric adenocarcinoma (2, 3) *H. pylori* permanent colonization in the gastric

mucosa (acquired from childhood) is associated with numerous gastroduodenal diseases, colorectal cancers, and MALT lymphoma with a high burden of morbidity and mortality (4). The prevalence of *H. pylori* in developed countries ranges 20-35%, reaching >65% in developing societies (5, 6). Bacterial virulence and genotype, host factors and epigenetics participate in the exacerbation of *H. pylori* infection. The bacterial colonization is mediated via some surface adhesins such as Bab, Sab,

**\*Corresponding Author:** Ghasemian Abdolmajid, Noncommunicable diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran  
Email: majidghasemian86@gmail.com  
<https://orcid.org/0000-0002-1243-6341>

Alsaadi Zainab H.: <https://orcid.org/0000-0002-9055-3404>  
Kadhim Hindi Nada Khazal: <https://orcid.org/0000-0001-9047-9315>  
Al-Marzoqi Ali H.: <https://orcid.org/0000-0002-8488-9964>  
Memariani Mojtaba: <https://orcid.org/0000-0002-4964-3117>  
Kohansal Maryam: <https://orcid.org/0000-0002-8231-1536>



HopZ, AlpA and OipA protein structures. BabA mostly participates in colonization via binding to Lewis blood group receptors on the gastric epithelial cells (6, 7). Moreover, OipA is a member of Hop protein family with a high prevalence among H. pylori isolates. SabA binds to sialic acid containing glycol-conjugate domains. Presumably, SabA causes atrophy and chronic inflammation owing to substitution of Lea and Lex sialic Lewis antigens instead of non-sialic antigens. Additionally, urease enzyme causes neutralization of gastric surface and bacterial survival. H. pylori cagA gene encodes CagA protein which is mostly associated with GC and duodenal carcinoma (9). Furthermore, VacA protein causes the epithelial cells vacuolation and apoptosis (9, 10). The association of major H. pylori virulence factors with GC necessitates the screening of these genes towards recognition of populations at higher risk for GC. The objective of our study was the screening of cagA, vacA, babA2, babB and oipA genes among H. pylori isolated from patients with GC, DN and PG.

## Materials & Methods

### Bacterial isolates and culture conditions

Following collection of consent from 500 patients with gastritis, duodenitis, duodenal ulcer, gastric ulcer and gastro-esophageal reflux, biopsy samples were obtained during May

2016- October 2020 in Babylon, Iraq. Those patients with antibiotic therapy during previous two weeks were excluded. The samples were homogenized and cultured onto the Brucella agar (Merk, Germany) in microaerophilic conditions supplemented with 5% sheep blood, 7% calf serum (Gibco, CA, USA), 5% CO<sub>2</sub> and antibiotics (vancomycin, amphotericin B and trimethoprim) (Sigma Aldrich) at 37°C for 5-7 days. Phenotypic identification included catalase, oxidase, urease and nitrate tests. Molecular identification was also performed. Patients were classified as H. pylori-infected only if all the tests were positive.

### Polymerase chain reaction

DNA extraction was performed using the Biospin Tissue Genomic DNA Extraction Kit (BioFlux, Japan). Molecular identification was done by amplification of glmM gene by the polymerase chain reaction (PCR). For glmM gene, PCR thermal profile was comprised of 35 cycles of denaturation (at 94 °C for 30 s), annealing (at 58°C for 30 s), extension (at 72°C for 30 s), and one final extension (at 72°C for 5 min). PCR reagents for master mix were applied as previously described (12). The adhesins (babA2, babB and oipA) and toxin (cagA and vacA) genes were also amplified using similar conditions using annealing temperatures depicted in Table 1.

Table1. Primer sequences used in this study

Primer	Sequence 5'-3'	Amplicon (bp)	Annealing (°C)	Reference
glmM	F: GGATAAGCTTTTAGGGGTGTTAGGGG R: GCTTACTTTCTAACACTAACGCGC	294	58	(13)
babB	F: ATGAAAAAAACCCTTTTAC R: CGAATTGCAAGTGATGGT	496	40	(14)
babA2	F: CCAAACGAAACAAAAAGCGT R: GCTTGTGTAAAAGCCGTCGT	271	45	(15)
oipA	F: GTTTTTGATGCATGGGATTT R: GTGCATCTCTTATGGCTTT	401	56	(16)



cagA	F: 5'- AATACACCAACGCCTCCAAG-3' R: 5'- TTGTTGGCGCTTGCTCTC-3'	499	60	(17)
vacA	F: 5'- GCCGATATGCAAATGAGCCGC-3' R: 5'- CAATCGTGTGGGTTCTGGAGC-3'	259	56	(18)

Data analysis

IBM SPSS 21 was employed for data analysis considering 95% confidence interval and p value<0.05 as significant finding. Comparison of isolates carrying each virulence factor was performed with isolates lacking virulence genes using unpaired chi-square test.

Results

Demographic data

The age range of patients was 14-69 years (mean age=47.34±7.23) including 269 (110 males and 159 female) H. pylori infected patients.


According to our inclusion criteria, none of patients had history of antibiotic consumption during previous two weeks. Family history of infection was observed in 179/269 (p=0.0371) of them.

H. pylori virulence genes

The rate of cagA, vacA, babA2, babB and oipA was 44.60%, 48.32%, 59.47%, 59.10% and 58.36%, respectively. The existence of all genes (in 133 isolates) was significantly associated with GC (p<0.0001), duodenal ulcer (DU, p<0.0001), pyloric gastritis (PG, p<0.0001) and duodenitis (DN, p=0.026) (Table2 and Figure1).

Table2. The existence of virulence genes in various origins

Endoscopic finding/gene	cagA	vacA	babA2	babB	oipA	p value
GC (n=83)	64.73%	55%	89%	54%	74%	0.019
DU (n=56)	63.43%	52.34%	68%	56%	69%	0.091
PG (n=121)	100%	58%	43%	61%	88%	0.041
DN (n=9)	100%	100%	64%	48%	84%	0.022



**Figure1.** PCR products of *oipA* (A), *glmM* (B), *babA2* (C), *vacA* (D), *babB* (E) and *cagA* (F) on 1% gel agarose and TBE buffer using 100bp DNA marker for all genes

## Discussion

*H. pylori* infection in human is influenced by numerous host and bacterial factors (19). Most of *H. pylori* strains express BabA2 (the only allelic subtype of the *bab* gene participating in Lewis adhesion) among those causing peptic ulcers or gastric cancer, rather than asymptomatic infection (20). The *babA2* gene has a significant association in GC via induction of inflammation and persistent colonization (21). The relation of *H. pylori*-mediated GC and development of gastric and duodenal cancer has been proven (21). In this study, *babA2* and *babB* were detected in 59.47% and 59.10% of isolates, respectively. Notably, *babA2* was observed in 89% of GC and 64% of DN strains were significantly higher than *babA2*-negative strains ( $<0.0001$  and  $0.028$ , respectively). Furthermore, *babB*-positive strains were significantly ( $0.042$ ) more associated with PG than negative strains. Indeed, *babB* gene exhibited no association with other complications. A previous study outlined that infection with *babA/B* mixed genotype strains amplified the risk of DU (22). The same was reported by Akbari et al. Patients

with GC and peptic ulcer disease (PUD) have higher levels of the *babA2* gene. The findings of this study demonstrated a link between the genotype of the *babA2* gene and negative clinical outcomes such as PUD and GC (23). In *H. pylori*, CagA is one of the most potent virulence factors. It is encoded by the *cag* PAI. Early in the 1990s, CagA was discovered, and is intimately linked with GC and peptic ulcers. The risk of developing gastritis and GC is higher in *H. pylori* strains with *cag* PAI compared to those without it (24). In addition, VacA is a pore-forming secreted toxin that binds to receptors such as receptor protein tyrosine phosphatase beta (RPTP). It is made up of N-terminal (p33) and C-terminal (p55) fragments (25). *Helicobacter pylori* secretes VacA toxins, which enhances the ability of the bacteria to colonize and contribute to gastric adenocarcinomas and peptic ulcers (26). In our study, the rate of *cagA* and *vacA* was 44.60% and 48.32%, respectively. The *cagA* was detected in 64.73% of GC, and 100% of PG and DN strains with a significant association. There has been a high rate of these genes



in clinical isolates causing gastrointestinal diseases (27, 28). In another study, by analysis of virulence factors [whole genome sequencing (WGS)], Imkamp et al also revealed that 56 percent of the isolates carried the *vacA* s1 allele, and that 43.9 percent of the *H. pylori* strains were *cagA*-positive. It was discovered that the presence of *cagA* was significantly ( $P=0.001$ ) correlated with the expression of *oipA*, *vacA* s1, *babA2*, and *hopQ* allele 1. The existence of the *cagA*, *vacA* s1, and *hopQ* alleles was also linked to the degree of gastritis and the prevalence of *H. pylori* in the GC (29). However, Dabiri et al observed no association between *cagA*, *vacA*, *cagE*, *babA2* status and clinical outcome among 160 isolates (14). Bartpho demonstrated that *vacA*, *babA2*, and *oipA* were predominant in gastric cancer, chronic gastritis and precancerous lesions (30). *OipA* encoded by the *HopH* gene is a protein of the outer membrane that is related to inflammation. An increased response to inflammation is produced by *OipA* positive *Helicobacter*. *OipA* positive *H. pylori* strains induce a greater degree of inflammation than *OipA* negative strains. Due to this, there is an increased risk of gastric cancer and peptic ulcers (31). We detected the *oipA* in 58.36% of strains which was significantly associated with GC (74%,  $P=0.0001$ ), PG (88%,  $p<0.0001$ ) and DN (84%,  $p<0.0001$ ). Braga et al observed that *oipA* existence and functionality was associated with development of gastric diseases and in the development of gastric cancer in particular (32). In an unexpected finding, Feili et al. identified a conflicting relationship between the *H. pylori oipA* genotype and the risk of peptic ulcerations (PUs) and GC in Iran (32). As reported by Kianmehr et al, *cagA*, *dupA*, and *babA* expression are significantly higher in GC patients. Screening these genes may aid in identifying people at higher risk of gastric ulcer disease and GC (33). A major limitation of our study was lack of gene expression assessment to confirm the activity of virulence genes.

## Conclusion

The existence of *H. pylori* virulence genes plays a crucial role in the development of gastric duodenal carcinoma which necessitates accurate control measure toward hindering the colonization of pathogenic strains.

## Conflict of interest

No conflict of interest is declared by the authors.

## Acknowledgement

The authors acknowledge the University of Babylon support for the study.

## References

1. McColl K. *Helicobacter pylori* infection. *N Engl J Med*. 2010;362(17):1597–604.
2. Wessler S. Emerging novel virulence factors of *Helicobacter pylori*. In: *Helicobacter pylori* research. Springer; 2016. p. 165–88.
3. Chen Z, Cai J, Chen Y, Wei J, Li H, Lu Y, et al. A meta-analysis of the association between the presence of *Helicobacter pylori* and periodontal diseases. *Medicine (Baltimore)*. 2019;98(22):4-24.
4. Kabamba ET, Tuan VP, Yamaoka Y. Genetic populations and virulence factors of *Helicobacter pylori*. *Infect Genet Evol*. 2018;60:109–16.
5. Backert S, Yamaoka Y. *Helicobacter pylori* Research. Springer; 2016.
6. Kao C-Y, Sheu B-S, Wu J-J. *Helicobacter pylori* infection: An overview of bacterial virulence factors and pathogenesis. *Biomed J*. 2016;39(1):14–23.
7. Mommersteeg MC, Yu J, Peppelenbosch MP, Fuhler GM. Genetic host factors in *Helicobacter pylori*-induced carcinogenesis: Emerging new paradigms. *Biochim Biophys Acta (BBA)-Reviews Cancer*. 2018;1869(1):42–52.
8. Ghotaslou R, Leylabadlo HE, Nasiri MJ, Dabiri H, Hashemi A. Risk of gastric cancer in association with *Helicobacter pylori* different virulence factors: A systematic review and meta-analysis. *Microb Pathog*. 2018;118:214–9.
9. Vaziri F, Tarashi S, Fateh A, Siadat SD. New insights of *Helicobacter pylori* host-pathogen interactions: The triangle of virulence factors, epigenetic modifications and non-coding RNAs. *World J Clin Cases*. 2018;6(5):64.
10. Kabamba ET, Yamaoka Y. *Helicobacter pylori* and related virulence factors for gastrointestinal diseases. In: *Gastric Cancer*. Springer; 2019. p. 31–50.
11. Miftahussurur M, Yamaoka Y, Graham DY. *Helicobacter pylori* as an oncogenic pathogen, revisited. *Expert Rev*



Mol Med. 2017;19: 25-32

12.Kanaan MHG, Al-Shadeedi SMJ, Al-Massody AJ, Ghasemian A. Drug resistance and virulence traits of *Acinetobacter baumannii* from Turkey and chicken raw meat. *Comp Immunol Microbiol Infect Dis*. 2020;70:101451.

13.Yakoob J, Abbas Z, Khan R, Tariq K, Awan S, Beg MA. Association of *Helicobacter pylori* and protozoal parasites in patients with chronic diarrhoea. *Br J Biomed Sci*. 2018;75(3):105–9.

14.Dabiri H, Jafari F, Baghaei K, Shokrzadeh L, Abdi S, Pourhoseingholi MA, et al. Prevalence of *Helicobacter pylori* *vacA*, *cagA*, *cagE*, *oipA*, *iceA*, *babA2* and *babB* genotypes in Iranian dyspeptic patients. *Microb Pathog*. 2017;105:226–30.

15.Shahi H, Reisi S, Bahreini R, Bagheri N, Salimzadeh L, Shirzad H. Association between *Helicobacter pylori* *cagA*, *babA2* virulence factors and gastric mucosal interleukin-33 mRNA expression and clinical outcomes in dyspeptic patients. *Int J Mol Cell Med*. 2015;4(4):227.

16. Sallas ML, Dos Santos MP, Orcini WA, David ÉB, Peruquetti RL, Payão SLM, et al. Status (on/off) of *oipA* gene: Their associations with gastritis and gastric cancer and geographic origins. *Arch Microbiol*. 2019;201(1):93–7.

17.Yanovich O, Doroshko M, Titov L. *Helicobacter pylori* genotypes among Belarus patients with gastroduodenal disorders and their association with clinical outcome. *Acta Microbiol Immunol Hung*. 2019;66(3):399–411.

18.Li N, Cao M, Yi S, Cheng J, Wang L, Tao Y, et al. Effects of the RNA-binding protein, KSRP, on innate immune response against *Helicobacter pylori* infection in mice. *Biochem Biophys Res Commun*. 2018;495(2):1573–9.

19.Sharafutdinov I, Backert S, Tegtmeyer N. Cortactin: a major cellular target of the gastric carcinogen *Helicobacter pylori*. *Cancers (Basel)*. 2020;12(1):159.

20.Hansen LM, Gideonsson P, Canfield DR, Borén T, Solnick J V. Dynamic expression of the BabA adhesin and its BabB paralog during *Helicobacter pylori* infection in rhesus macaques. *Infect Immun*. 2017;85(6):e00094-17.

21.Ansari S, Yamaoka Y. *Helicobacter pylori* BabA in adaptation for gastric colonization. *World J Gastroenterol*. 2017;23(23):4158.

22.Saberi S, Schmidt A, Eybpoosh S, Esmaili M, Talebkhan Y, Mohajerani N, et al. *Helicobacter pylori* strains from duodenal ulcer patients exhibit mixed *babA/B* genotypes with low levels of BabA adhesin and Lewis b binding. *Dig Dis Sci*. 2016;61(10):2868–77.

23.Akbari S, Rezaeian T, Mohammadzadeh R, Meshkat Z, Namdar AB, Aryan E, et al. Investigation of association between *iceA*, *babA2*,

and *oipA* genotypes of *Helicobacter pylori* and IL-8-251 T> A polymorphism with clinical outcomes in *Helicobacter pylori*-infected Iranian patients. *Gene Reports*. 2021;24:101210.

24.Vital JS, Tanoeiro L, Lopes-Oliveira R, Vale FF. Biomarker Characterization and Prediction of Virulence and Antibiotic Resistance from *Helicobacter pylori* Next Generation Sequencing Data. *Biomolecules*. 2022;12(5):691.

25.Alexander SM, Retnakumar RJ, Chouhan D, Devi TNB, Dharmaseelan S, Devadas K, et al. *Helicobacter pylori* in human stomach: the inconsistencies in clinical outcomes and the probable causes. *Front Microbiol*. 2021;12:713955.

26.Brasil-Costa I, Souza C de O, Monteiro LCR, Santos MES, Oliveira EHC De, Burbano RMR. *H. pylori* Infection and Virulence Factors *cagA* and *vacA* (s and m Regions) in Gastric Adenocarcinoma from Pará State, Brazil. *Pathogens*. 2022;11(4):414.

27.Kocazeybek B, Ergin S, Caliskan R, Demiryas S, Kepil N, Dinc O, et al. The importance of the association of *cagL* with *cagA*, *vacAs/m* and *babA* gene regions in patients with gastric cancer, duodenal ulcer and non-ulcer dyspepsia related to *H. pylori*: First in vitro study from Turkey. *Int J Infect Dis*. 2018;73:154.

28.Carlosama-Rosero YH, Bolaños-Bravo H, Sierra-Tórres CH, Rosero EA. Association of the *Helicobacter pylori* *cagA*, *vacA*, and *iceA* genotypes with chronic follicular gastritis in a Colombian population at high risk for gastric cancer. *Rev Gastroenterol México (English Ed)*. 2019;84(2):158–64.

29.Imkamp F, Lauener FN, Pohl D, Lehours P, Vale FF, Jehanne Q, et al. Rapid characterization of virulence determinants in *Helicobacter pylori* isolated from non-atrophic gastritis patients by next-generation sequencing. *J Clin Med*. 2019;8(7):1030.

30.Bartpho TS, Wattanawongdon W, Tongtawee T, Paoi C, Kangwantis K, Dechsukhum C. Precancerous gastric lesions with *Helicobacter pylori* *vacA*+/*babA2*+/*oipA*+ genotype increase the risk of gastric cancer. *Biomed Res Int*. 2020;2020.

31.Wang S, Wang D, Duan Y, Zhou Z, Gao W, Zhang L. Cellular Nanosponges for Biological Neutralization. *Adv Mater*. 2022;34(13):2107719.

32.Feili O, Bakhti SZ, Latifi-Navid S, Zahri S, Yazdanbod A. Contrasting association of *Helicobacter pylori* *oipA* genotype with risk of peptic ulceration and gastric cancer. *Infect Genet Evol*. 2021;89:104720.

33.Kianmehr M, Hormati A, Zargar M, Fateh R, Nazari R. *Helicobacter Pylori* Different Virulence Genes and the Risk of Gastric Cancer in Iranian Patients. 2020.